Related Experiment Video

Updated: May 26, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

Seng-Ryong Woo1, Meghan E Turnis, Monica V Goldberg

  • 1Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Cancer Research
|December 22, 2011
PubMed

Insights

Dual blockade of PD-1 and LAG-3 inhibitory receptors synergistically enhances anti-tumor immunity and overcomes immune tolerance. This combination therapy shows promise for treating cancers resistant to single-agent treatments.

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Inhibitory receptors on immune cells regulate anti-tumor responses and immune escape in cancer.
  • While CTLA-4 is a known immune checkpoint, the synergistic roles of PD-1 and LAG-3 are less understood.
  • Understanding these interactions is crucial for developing effective cancer immunotherapies.

Purpose of the Study:

  • To investigate the synergistic interactions between PD-1 and LAG-3 inhibitory pathways in cancer.
  • To evaluate the efficacy of dual blockade of PD-1 and LAG-3 in preclinical cancer models.
  • To explore the role of these pathways in self-tolerance.

Main Methods:

  • Analysis of PD-1 and LAG-3 coexpression on tumor-infiltrating T cells.
  • Treatment of tumor-bearing mice with single and dual anti-PD-1/anti-LAG-3 antibodies.
  • Generation and analysis of single and dual knockout mice (Lag3(-/-)Pdcd1(-/-)).

Main Results:

  • Extensive coexpression of PD-1 and LAG-3 was observed on tumor-infiltrating CD4(+) and CD8(+) T cells.
  • Dual anti-PD-1/anti-LAG-3 antibody treatment led to tumor eradication in most mice, outperforming single antibody treatments.
  • Dual knockout mice exhibited abrogated self-tolerance, leading to autoimmunity but also enhanced tumor clearance and survival.

Conclusions:

  • PD-1 and LAG-3 pathways exhibit strong synergy in regulating tolerance to self and tumor antigens.
  • Dual blockade of PD-1 and LAG-3 represents a potent combinatorial strategy for cancer immunotherapy.
  • This approach holds promise for overcoming resistance to current single-agent checkpoint inhibitors.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...